nVision Medical Company
.jpg)
Acquired by Boston Scientific. nVision developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Recent studies have confirmed that several major types of ovarian cancer appear to originate from the fallopian tubes.
Industry:
General Health Care
Headquarters:
San Bruno, California, United States
Founded Date:
01-01-2009
Employees Number:
1-10
Funding Status:
M&A
Investors Number:
9
Total Funding:
$16,405,000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2016-07-21
Last Funding Type:
Series B
Register and Claim Ownership